Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors | bioRxiv
Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutations | medRxiv
![PDF] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0cf466fd259f6bee54109793ae154a69035d609c/7-Table4-1.png "PDF] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations | Semantic Scholar")
PDF] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations | Semantic Scholar
PTEN/MMAC1 mutations found in lung cancers | Download Table
pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma | Communications Biology
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing - ScienceDirect
Proteomic and Phosphoproteomic Analyses Reveal the Oncogenic Role of PTK7-NDRG1 Axis in Non-small-cell Lung Cancer Cell Resistance to AZD9291 | ACS Chemical Biology
Cancers | Free Full-Text | Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy
Frontiers | Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I–III Non-small Cell Lung Cancer Patients
IJMS | Free Full-Text | The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer
Frontiers | Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
EGFL7 drives the evolution of resistance to EGFR inhibitors in lung cancer by activating NOTCH signaling | Cell Death & Disease
Prognosis of Different Types of Non-Small Cell Lung Cancer Progression: Current State and Perspectives | Cell Physiol Biochem
Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR - Ariyasu - 2021 - Cancer Science - Wiley Online Library
Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis - Liu - 2020 - Cancer Communications - Wiley Online Library
Frontiers | mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications
Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center
IKKα Promotes the Progression and Metastasis of Non-Small Cell Lung Cancer Independently of its Subcellular Localization - ScienceDirect
IKKα Promotes the Progression and Metastasis of Non-Small Cell Lung Cancer Independently of its Subcellular Localization - ScienceDirect
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells - ScienceDirect
Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes | IntechOpen
Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties
Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells | Scientific Reports
Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutations | medRxiv
PDF) Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis
Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation | Oncogene
